Supplementary Data 2 from A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
Year: 2023
Type: supplementary-materials
Abstract: The figures show that patients received 10 mg ulocuplumab could reach higher concentration peak and larger dose-corrected area under curve (both p < 0.001).
Authors: Irene M. Ghobrial, Chia-Jen Liu, Robert A. Redd, Raymond P. Perez, Rachid Baz, Oksana Zavidij, Romanos Sklavenitis-Pistofidis, Paul G. Richardson, Kenneth C. Anderson, Jacob Laubach, Patrick Henrick, Alexandra Savell, Kaitlen Reyes, Kalvis Hornburg, Stacey Chuma, Peter Sabbatini, Michael D. Robbins, Pamela S. Becker
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361967478